# Octave Life Sciences

> Octave Life Sciences is a VC fund in Mumbai backing Health Care and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Mumbai, India
- Total investments: 3
- Last investment: Aug 2019
- Lead investor: 33%
- Last updated: Aug 2026
- Website: http://www.octavelifesciences.com/

Octave Life Sciences is a pharmaceutical firm that proactively markets high-quality medicinal goods. The firm has been promoting medicinal items in India and overseas for several years. In every part of the pharmaceutical sector, the marketed goods fulfill all worldwide requirements. They are concentrating their efforts on export markets. They aregrowing from strength to strength in these areas, thanks to a very strong marketing staff, and are making huge advances every day with their over 15+ items. The firm is gaining global prominence and plans to expand in the near future.The company was founded in 2018 and is headquartered in Mumbai, India.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 33% |
| Biotechnology | 1 | 33% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| D&D Pharmatech | D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company's product pipeline focuses on a range of indications including neurodegenerative, metabolic and fibrotic diseases,providing the opportunity to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients. | $137.1M | Series B | Aug 14, 2019 |  |
| Neuraly | Neuraly, a startup biotech company, was formed in 2016 following foundational research by world class neuroscientists led by Ted Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and Director of the Institute for Cell Engineering at the Johns Hopkins School of Medicine. Following the acquisition of exclusivelicenses to patents covering the composition of matter and methods of use, research supporting the development of NLY01 was recently published in Nature Medicine1. These data demonstrated the critical role of the glial compartment of the neural tissue in the pathogenesis of neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. | $36M | Series A | Jul 18, 2018 |  |
| D&D Pharmatech | D&D Pharmatech is a operator of a holding company created to fund the development of therapeutic medicines through disease-specific subsidiary companies founded and guided by top-tier medical research faculty. The company's product pipeline focuses on a range of indications including neurodegenerative, metabolic and fibrotic diseases,providing the opportunity to accelerate the translation of cutting-edge research into lifesaving therapeutic products for patients. | $36M | Series A | Jan 01, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [LB Investment](https://shizune.co/investors/profile/lb-investment) — VC Fund, 3 deals together
- [Magna Investment](https://shizune.co/investors/profile/magna-investment) — VC Fund, 3 deals together
- [Smilegate Investment](https://shizune.co/investors/profile/smilegate-investment) — VC Fund, 3 deals together
- [Dongkoo Bio&Pharma](https://shizune.co/investors/profile/dongkoo-bio-pharma) — VC Fund, 2 deals together
- [Geon Investment](https://shizune.co/investors/profile/geon-investment) — VC Fund, 2 deals together
- [InterVest Co.](https://shizune.co/investors/profile/intervest-co) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in South Korea](https://shizune.co/investors/health-care-vc-funds-south-korea)
- [Health Care Investors in South Korea](https://shizune.co/investors/health-care-investors-south-korea)

## FAQ

### What does Octave Life Sciences invest in?

Octave Life Sciences invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Octave Life Sciences last invest?

The most recent investment recorded for Octave Life Sciences closed in Aug 2019. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co